Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $3.5 million.

  • Aytu Biopharma's Change in Accured Expenses fell 5272.23% to $3.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $364000.0, marking a year-over-year increase of 11114.51%. This contributed to the annual value of $886000.0 for FY2025, which is 10967.14% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Change in Accured Expenses is $3.5 million, which was down 5272.23% from -$1.6 million recorded in Q3 2025.
  • Aytu Biopharma's Change in Accured Expenses' 5-year high stood at $8.0 million during Q1 2023, with a 5-year trough of -$14.5 million in Q2 2022.
  • For the 5-year period, Aytu Biopharma's Change in Accured Expenses averaged around -$849100.0, with its median value being -$736500.0 (2024).
  • As far as peak fluctuations go, Aytu Biopharma's Change in Accured Expenses crashed by 57467.36% in 2022, and later soared by 87987.8% in 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Accured Expenses (Quarter) stood at -$3.9 million in 2021, then skyrocketed by 162.73% to $2.5 million in 2022, then crashed by 48.52% to $1.3 million in 2023, then soared by 474.23% to $7.3 million in 2024, then tumbled by 52.72% to $3.5 million in 2025.
  • Its Change in Accured Expenses was $3.5 million in Q4 2025, compared to -$1.6 million in Q3 2025 and -$3.1 million in Q2 2025.